MedPath

A Trial on Contrast-enhanced Ultrasound Versus Conventional Ultrasound Guided Biopsy of Liver Neoplasms

Not Applicable
Conditions
Liver Neoplasms
Interventions
Other: CEUS guided biopsy
Other: US guided biopsy
Device: Ultrasound
Registration Number
NCT02413437
Lead Sponsor
Peking University Cancer Hospital & Institute
Brief Summary

The purpose of this study is to estimate the clinical value of contrast-enhanced ultrasound in percutaneous biopsy for liver occupied lesion.

Detailed Description

The patients with liver neoplasms who need receive percutaneous biopsy were randomized into contrast-enhanced ultrasound(CEUS) group and conventional ultrasound(US) group.The aims include:

1. Comparison the diagnostic accuracy rate, specificity and sensitivity between CEUS and US group.

2. Comparison the diagnostic accuracy rate specificity and sensitivity between smaller(\<3cm) and larger(≥3cm) nodule group.

3. To explore operating strategy of contrast-enhanced ultrasound guided biopsy.

4. To evaluate economic efficiency of contrast-enhanced ultrasound guided biopsy compared with conventional ultrasound guided biopsy.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
2088
Inclusion Criteria
  • patients with liver occupied lesion who cannot be diagnosed by imaging examination or need pathological results
Exclusion Criteria
  • severe anemia
  • PLT<60000/mm3,prothrombin activityprothrombin time activity<70%
  • women during menstruation, pregnancy, child birth and baby nursing period
  • patients with severe mental disorder
  • cardiopulmonary failure

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
US guided biopsyUltrasoundBiopsy was operated under conventional ultrasound-guided
CEUS guided biopsyCEUS guided biopsyBiopsy was operated under contrast-enhanced ultrasound-guided
US guided biopsyUS guided biopsyBiopsy was operated under conventional ultrasound-guided
CEUS guided biopsyUltrasoundBiopsy was operated under contrast-enhanced ultrasound-guided
Primary Outcome Measures
NameTimeMethod
diagnostic accuracy12 months

diagnostic accuracy=(true positive+ ture negative)/number of parcitipants

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Beijing Cancer Hospital

🇨🇳

Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath